Mayne Pharma Group Ltd (MYX)
Australian Securities Exchange · Australia · prices in AUD · close of 20 Oct 2026
Key indicators
| Last close | AUD 2.540 |
|---|---|
| 52-week range | 2.040 – 6.250 |
| Return, 1 month / 3 months | −10.9% / −7.0% |
| Return, 1 year / 3 years | −59.0% / −35.4% |
| Trend | Below its 200-day average |
| RSI (14) | 36 |
| Volatility (1 year) | 70.7% |
| Worst drawdown (1 year) | -65.6% |
| Average daily value traded | 0.70M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Mayne Pharma Group is a specialty pharmaceutical company based in Australia that develops, manufactures and markets prescription medicines. Its portfolio includes generic and branded products in areas such as women's health, dermatology and oral drug delivery, and it supplies pharmacies, hospitals and healthcare providers in Australia and overseas. The company also provides contract development and manufacturing services for other pharmaceutical firms, making tablets, capsules and other dose forms at its production sites.
The shares are listed on the Australian Securities Exchange in Australia under the code MYX, and the price on this page is in Australian dollars (AUD). Our dividend records, which start in 2019, show payments in one calendar year. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Mayne Pharma Group Ltd (MYX) trades on the Australian Securities Exchange in Australia. It last closed at AUD 2.540 on 20 October 2026.
Its price-based Market X-Ray is 53 out of 100 (a fair price profile), ranking 834 of 1,815 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 59.0% and over the last three months it fell 7.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 60 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -5.5% | ||
| From 52-week high | -59.0% | ||
| Momentum | 44 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -7.0% | ||
| 6-month return | -1.2% | ||
| 12-month return, skipping the last month | -54.0% | ||
| Stability (higher is calmer) | 42 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 70.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -65.6% | ||
| Liquidity | 77 · Strong | Trades actively. | |
| Average daily value traded | 0.70M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 1 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | −10.9% |
| 3 months | −7.0% |
| 6 months | −1.2% |
| 1 year | −59.0% |
| 3 years | −35.4% |
| 5 years | −61.3% |
Signals
| 50-day / 200-day average | 2.967 / 2.689 |
|---|---|
| Golden / death cross (60 days) | Golden, 40 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.112 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 Jan 2023 | AUD 0.5440 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.